Erratum: Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor (PLoS Pathogens (2016) 12:3 (e1005531) DOI: 10.1371/journal.ppat.1005531);Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor

PLoS Pathogens

Volumn 12, Issue 3, 2016, Pages

  Kim, Yunjeong ^a   Liu, Hongwei ^b   Galasiti Kankanamalage, Anushka C ^c   Weerasekara, Sahani ^a   Hua, Duy H ^a   Groutas, William C ^c   Chang, Kyeong Ok ^a   Pedersen, Niels C ^b  

^a KANSAS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WICHITA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GC 376; NP I64; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; AUTOPSY; BLOOD CHEMISTRY; BLOOD LEVEL; CAT; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONAVIRUS INFECTION; DISEASE COURSE; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; IN VITRO STUDY; JAUNDICE; LYMPHOCYTOPENIA; MALE; NONHUMAN; PANCREATITIS; PERITONITIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEVERE ACUTE RESPIRATORY SYNDROME; SINGLE DRUG DOSE; WEIGHT REDUCTION; X RAY CRYSTALLOGRAPHY; ANIMAL; CAT DISEASES; CORONAVIRUS INFECTIONS; DRUG EFFECTS; FELINE CORONAVIRUS; FELINE INFECTIOUS PERITONITIS; SYNTHESIS; VIROLOGY; VIRULENCE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CAT DISEASES; CATS; CORONAVIRUS INFECTIONS; CORONAVIRUS, FELINE; FELINE INFECTIOUS PERITONITIS; FEMALE; MALE; PROTEASE INHIBITORS; VIRULENCE; VIRUS REPLICATION;

EID: 84962460001     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005650     Document Type: Erratum

References (57)

1. King AM, Lefkowitz E, Adams MJ, Carstens EB, Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses1ed: Elsevier; 2011.
2. Lai MM, Cavanagh D, The molecular biology of coronaviruses. Adv Virus Res. 1997;48:1–100. 9233431.
3. Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, et al. Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 2012;86(7):3995–4008. Epub 2012/01/27. doi: 10.1128/JVI.06540-11 [pii]. 22278237; PubMed Central PMCID: PMCPMC3302495.
4. Adedeji AO, Sarafianos SG, Antiviral drugs specific for coronaviruses in preclinical development. Curr Opin Virol. 2014;8:45–53. doi: 10.1016/j.coviro.2014.06.00224997250; PubMed Central PMCID: PMCPMC4195804.
5. Kumar V, Jung YS, Liang PH, Anti-SARS coronavirus agents: a patent review (2008—present). Expert Opin Ther Pat. 2013;23(10):1337–48. doi: 10.1517/13543776.2013.82315923905913.
6. De Clercq E, Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther. 2006;4(2):291–302. Epub 2006/04/07. doi: 10.1586/14787210.4.2.29116597209.
7. Hilgenfeld R, From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281(18):4085–96. doi: 10.1111/febs.1293625039866.
8. Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005;3(10):e324. Epub 2005/09/01. 05-PLBI-RA-0435R1 [pii] doi: 10.1371/journal.pbio.003032416128623; PubMed Central PMCID: PMCPMC1197287.
9. Rasschaert D, Duarte M, Laude H, Porcine respiratory coronavirus differs from transmissible gastroenteritis virus by a few genomic deletions. J Gen Virol. 1990;71 (Pt 11):2599–607. 2174956.
10. Pedersen NC, A review of feline infectious peritonitis virus infection: 1963–2008. J Feline Med Surg. 2009;11(4):225–58. Epub 2009/03/04. doi: 10.1016/j.jfms.2008.09.008 S1098-612X(09)00017-5 [pii]. 19254859.
11. Pedersen NC, An update on feline infectious peritonitis: Virology and immunopathogenesis. Veterinary Journal. 2014;201(2):123–32. doi: 10.1016/j.tvjl.2014.04.017 WOS:000340225200002.
12. Pedersen NC, Liu H, Scarlett J, Leutenegger CM, Golovko L, Kennedy H, et al. Feline infectious peritonitis: role of the feline coronavirus 3c gene in intestinal tropism and pathogenicity based upon isolates from resident and adopted shelter cats. Virus Res. 2012;165(1):17–28. Epub 2012/01/28. doi: 10.1016/j.virusres.2011.12.02022280883.
13. Pedersen NC, Liu H, Dodd KA, Pesavento PA, Significance of coronavirus mutants in feces and diseased tissues of cats suffering from feline infectious peritonitis. Viruses. 2009;1(2):166–84. doi: 10.3390/v102016621994544; PubMed Central PMCID: PMCPMC3185486.
14. Chang HW, Egberink HF, Halpin R, Spiro DJ, Rottier PJ, Spike protein fusion Peptide and feline coronavirus virulence. Emerg Infect Dis. 2012;18(7):1089–95. Epub 2012/06/20. doi: 10.3201/eid1807.12014322709821; PubMed Central PMCID: PMCPMC3376813.
15. Barker EN, Tasker S, Gruffydd-Jones TJ, Tuplin CK, Burton K, Porter E, et al. Phylogenetic analysis of feline coronavirus strains in an epizootic outbreak of feline infectious peritonitis. J Vet Intern Med. 2013;27(3):445–50. doi: 10.1111/jvim.1205823517431.
16. Licitra BN, Millet JK, Regan AD, Hamilton BS, Rinaldi VD, Duhamel GE, et al. Mutation in spike protein cleavage site and pathogenesis of feline coronavirus. Emerg Infect Dis. 2013;19(7):1066–73. doi: 10.3201/eid1907.12109423763835; PubMed Central PMCID: PMCPMC3713968.
17. Pedersen NC, Eckstrand C, Liu H, Leutenegger C, Murphy B, Levels of feline infectious peritonitis virus in blood, effusions, and various tissues and the role of lymphopenia in disease outcome following experimental infection. Vet Microbiol. 2015;175(2–4):157–66. doi: 10.1016/j.vetmic.2014.10.02525532961.
18. Chan PK, Chen GG, Mechanisms of lymphocyte loss in SARS coronavirus infection. Hong Kong Med J. 2008;14Suppl 4:21–6. 18708670.
19. Takano T, Hohdatsu T, Hashida Y, Kaneko Y, Tanabe M, Koyama H, A "possible" involvement of TNF-alpha in apoptosis induction in peripheral blood lymphocytes of cats with feline infectious peritonitis. Vet Microbiol. 2007;119(2–4):121–31. Epub 2006/10/19. S0378-1135(06)00357-9 [pii] doi: 10.1016/j.vetmic.2006.08.03317046178.
20. Takano T, Hohdatsu T, Toda A, Tanabe M, Koyama H, TNF-alpha, produced by feline infectious peritonitis virus (FIPV)-infected macrophages, upregulates expression of type II FIPV receptor feline aminopeptidase N in feline macrophages. Virology. 2007;364(1):64–72. Epub 2007/03/27. S0042-6822(07)00119-5 [pii] doi: 10.1016/j.virol.2007.02.00617382365.
21. Dean GA, Olivry T, Stanton C, Pedersen NC, In vivo cytokine response to experimental feline infectious peritonitis virus infection. Vet Microbiol. 2003;97(1–2):1–12. Epub 2003/11/26. S0378113503002918 [pii]. 14637034.
22. de Groot-Mijnes JD, van Dun JM, van der Most RG, de Groot RJ, Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease. J Virol. 2005;79(2):1036–44. Epub 2004/12/23. 79/2/1036 [pii] doi: 10.1128/JVI.79.2.1036-1044.200515613332; PubMed Central PMCID: PMCPMC538555.
23. Ritz S, Egberink H, Hartmann K, Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J Vet Intern Med. 2007;21(6):1193–7. Epub 2008/01/17. 18196725.
24. Fischer Y, Ritz S, Weber K, Sauter-Louis C, Hartmann K, Randomized, placebo controlled study of the effect of propentofylline on survival time and quality of life of cats with feline infectious peritonitis. J Vet Intern Med. 2011;25(6):1270–6. Epub 2011/11/19. doi: 10.1111/j.1939-1676.2011.00806.x22092616.
25. Pedersen NC, An update on feline infectious peritonitis: Diagnostics and therapeutics. Veterinary Journal. 2014;201(2):133–41. doi: 10.1016/j.tvjl.2014.04.016 WOS:000340225200003.
26. Rohrbach BW, Legendre AM, Baldwin CA, Lein DH, Reed WM, Wilson RB, Epidemiology of feline infectious peritonitis among cats examined at veterinary medical teaching hospitals. J Am Vet Med Assoc. 2001;218(7):1111–5. Epub 2001/04/25. 11318361.
27. Heeney JL, Evermann JF, McKeirnan AJ, Marker-Kraus L, Roelke ME, Bush M, et al. Prevalence and implications of feline coronavirus infections of captive and free-ranging cheetahs (Acinonyx jubatus). J Virol. 1990;64(5):1964–72. Epub 1990/05/01. 2157864; PubMed Central PMCID: PMCPMC249350.
28. Kim Y, Lovell S, Tiew KC, Mandadapu SR, Alliston KR, Battaile KP, et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol. 2012;86(21):11754–62. Epub 2012/08/24. JVI.01348-12 [pii] doi: 10.1128/JVI.01348-1222915796.
29. Kim Y, Mandadapu SR, Groutas WC, Chang KO, Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease. Antiviral Res. 2013;97(2):161–8. Epub 2012/12/12. S0166-3542(12)00260-4 [pii] doi: 10.1016/j.antiviral.2012.11.00523219425.
30. Kim Y, Shivanna V, Narayanan S, Prior AM, Weerasekara S, Hua DH, et al. Broad-spectrum inhibitors against 3C-Like proteases of feline coronaviruses and feline caliciviruses. J Virol. 2015;89(9):4942–50. Epub 2015/02/20. doi: 10.1128/JVI.03688-1425694593.
31. Deng X, Agnihothram S, Mielech AM, Nichols DB, Wilson MW, StJohn SE, et al. A chimeric virus-mouse model system for evaluating the function and inhibition of papain-like proteases of emerging coronaviruses. J Virol. 2014;88(20):11825–33. doi: 10.1128/JVI.01749-1425100850; PubMed Central PMCID: PMCPMC4178736.
32. Chang KO, Takahashi D, Prakash O, Kim Y, Characterization and inhibition of norovirus proteases of genogroups I and II using a fluorescence resonance energy transfer assay. Virology. 2012;423(2):125–33. Epub 2011/12/28. S0042-6822(11)00559-9 [pii] doi: 10.1016/j.virol.2011.12.00222200497.
33. Schechter I, Berger A, On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun. 1967;27(2):157–62. Epub 1967/04/20. S0006-291X(67)80055-X [pii]. 6035483.
34. Pedersen NC, Liu H, Gandolfi B, Lyons LA, The influence of age and genetics on natural resistance to experimentally induced feline infectious peritonitis. Vet Immunol Immunopathol. 2014;162(1–2):33–40. doi: 10.1016/j.vetimm.2014.09.00125265870.
35. Wang YT, Chueh LL, Wan CH, An eight-year epidemiologic study based on baculovirus-expressed type-specific spike proteins for the differentiation of type I and II feline coronavirus infections. BMC Vet Res. 2014;10:186.doi: 10.1186/s12917-014-0186-725123112; PubMed Central PMCID: PMCPMC4236817.
36. Kummrow M, Meli ML, Haessig M, Goenczi E, Poland A, Pedersen NC, et al. Feline coronavirus serotypes 1 and 2: seroprevalence and association with disease in Switzerland. Clin Diagn Lab Immunol. 2005;12(10):1209–15. Epub 2005/10/08. 12/10/1209 [pii] doi: 10.1128/CDLI.12.10.1209-1215.200516210485; PubMed Central PMCID: PMCPMC1247821.
37. Benetka V, Kubber-Heiss A, Kolodziejek J, Nowotny N, Hofmann-Parisot M, Mostl K, Prevalence of feline coronavirus types I and II in cats with histopathologically verified feline infectious peritonitis. Vet Microbiol. 2004;99(1):31–42. Epub 2004/03/17. doi: 10.1016/j.vetmic.2003.07.010 S0378113503003821 [pii]. 15019109.
38. Hohdatsu T, Okada S, Ishizuka Y, Yamada H, Koyama H, The prevalence of types I and II feline coronavirus infections in cats. J Vet Med Sci. 1992;54(3):557–62. Epub 1992/06/01. 1322718.
39. Schmittgen TD, Livak KJ, Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8. 18546601.
40. Needle D, Lountos GT, Waugh DS, Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity. Acta Crystallogr D Biol Crystallogr. 2015;71(Pt 5):1102–11. doi: 10.1107/S139900471500352125945576; PubMed Central PMCID: PMCPMC4427198.
41. Shimamoto Y, Hattori Y, Kobayashi K, Teruya K, Sanjoh A, Nakagawa A, et al. Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors. Bioorg Med Chem. 2015;23(4):876–90. doi: 10.1016/j.bmc.2014.12.02825614110.
42. DeDiego ML, Nieto-Torres JL, Regla-Nava JA, Jimenez-Guardeno JM, Fernandez-Delgado R, Fett C, et al. Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol. 2014;88(2):913–24. doi: 10.1128/JVI.02576-1324198408; PubMed Central PMCID: PMCPMC3911641.
43. Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 2009;395(2):210–22. Epub 2009/10/27. S0042-6822(09)00583-2 [pii] doi: 10.1016/j.virol.2009.09.02319853271.
44. Zhao J, Wohlford-Lenane C, Zhao J, Fleming E, Lane TE, McCray PB, Jr.et al. Intranasal treatment with poly(I*C) protects aged mice from lethal respiratory virus infections. J Virol. 2012;86(21):11416–24. doi: 10.1128/JVI.01410-1222915814; PubMed Central PMCID: PMCPMC3486278.
45. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R, Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300(5626):1763–7. Epub 2003/05/15. doi: 10.1126/science.1085658 1085658 [pii]. 12746549.
46. Ghosh AK, Gong G, Grum-Tokars V, Mulhearn DC, Baker SC, Coughlin M, et al. Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett. 2008;18(20):5684–8. Epub 2008/09/18. doi: 10.1016/j.bmcl.2008.08.082 S0960-894X(08)00986-4 [pii]. 18796354; PubMed Central PMCID: PMCPMC2745596.
47. Lee CC, Kuo CJ, Ko TP, Hsu MF, Tsui YC, Chang SC, et al. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds. J Biol Chem. 2009;284(12):7646–55. Epub 2009/01/16. M807947200 [pii] doi: 10.1074/jbc.M80794720019144641; PubMed Central PMCID: PMC2658058.
48. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A. 2003;100(23):13190–5. Epub 2003/10/31. doi: 10.1073/pnas.1835675100 1835675100 [pii]. 14585926.
49. Liang PH, Characterization and inhibition of SARS-coronavirus main protease. Curr Top Med Chem. 2006;6(4):361–76. Epub 2006/04/14. 16611148.
50. Kuo CJ, Liu HG, Lo YK, Seong CM, Lee KI, Jung YS, et al. Individual and common inhibitors of coronavirus and picornavirus main proteases. FEBS Lett. 2009;583(3):549–55. Epub 2009/01/27. S0014-5793(09)00016-7 [pii] doi: 10.1016/j.febslet.2008.12.05919166843.
51. Yang S, Chen SJ, Hsu MF, Wu JD, Tseng CTK, Liu YF, et al. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. Journal of Medicinal Chemistry. 2006;49(16):4971–80. doi: 10.1021/jm0603926 WOS:000239459800021. 16884309
52. Deng X, StJohn SE, Osswald HL, O'Brien A, Banach BS, Sleeman K, et al. Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance. J Virol. 2014;88(20):11886–98. Epub 2014/08/08. doi: 10.1128/JVI.01528-14 JVI.01528-14 [pii]. 25100843; PubMed Central PMCID: PMCPMC4178758.
53. Prior AM, Kim Y, Weerasekara S, Moroze M, Alliston KR, Uy RA, et al. Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors. Bioorg Med Chem Lett. 2013;23(23):6317–20. Epub 2013/10/16. doi: 10.1016/j.bmcl.2013.09.070 S0960-894X(13)01144-X [pii]. 24125888; PubMed Central PMCID: PMCPMC3863581.
54. Pedersen NC, Liu H, Durden M, Lyons LA, Natural resistance to experimental feline infectious peritonitis virus infection is decreased rather than increased by positive genetic selection. Veterinary Immunology and Immunopathology. 2016;171:17–20. doi: 10.1016/j.vetimm.2016.01.00226964713
55. Beaucourt S, Bordera AV, Coffey LL, Gnadig NF, Sanz-Ramos M, Beeharry Y, et al. Isolation of Fidelity Variants of RNA Viruses and Characterization of Virus Mutation Frequency. Jove-J Vis Exp. 2011;(52). UNSP e2953 doi: 10.3791/2953 WOS:000209214900044.
56. Kuntal BK, Aparoy P, Reddanna P, EasyModeller: A graphical interface to MODELLER. BMC Res Notes. 2010;3:226. Epub 2010/08/18. doi: 10.1186/1756-0500-3-226 1756-0500-3-226 [pii]. 20712861; PubMed Central PMCID: PMCPMC2936912.
57. The PyMOL Molecular Graphics System VS, LLC.